NESIC chooses Cloudbrink SASE to power managed service
19 nov. 2024 08h00 HE
|
Cloudbrink
NEC Networks & System Integration Corporation (NESIC) selects the Cloudbrink SASE service as the foundation of its Virtual Trusted Overlay Network
Cloudbrink grows its global footprint with new NEC Networks & System Integration Corporation deal for the Philippines
04 déc. 2023 11h05 HE
|
Cloudbrink
As part of Cloudbrink's global expansion, they are pleased to announce signing up NEC Networks & System Integration Corporation for the Philippines.
Cloudbrink-NEC Networks & System Integration Corporation deal delivers speed boost for Philippines hybrid workforce
28 nov. 2023 19h00 HE
|
Cloudbrink
Cloudbrink, has extended its partnership with NEC Networks & System Integration Corporation to the Philippines.
Nytt antal aktier och röster i IBT
31 juil. 2023 04h00 HE
|
Infant Bacterial Therapeutics AB
Antalet aktier och röster i Infant Bacterial Therapeutics AB (publ) har förändrats med anledning av den nyligen genomförda företrädesemissionen (för mer information, se bolagets pressmeddelande den 4...
New number of shares and votes in IBT
31 juil. 2023 04h00 HE
|
Infant Bacterial Therapeutics AB
The number of shares and votes in Infant Bacterial Therapeutics AB (publ) has changed due to the recently completed rights issue (for further information, see the company’s press release on 4 July...
IBT offentliggör utfall i företrädesemissionen
04 juil. 2023 02h30 HE
|
Infant Bacterial Therapeutics AB
EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, HELT ELLER DELVIS, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, KANADA, NYA ZEELAND, HONGKONG, JAPAN, SCHWEIZ, SINGAPORE, SYDAFRIKA,...
IBT announces outcome of its rights issue
04 juil. 2023 02h30 HE
|
Infant Bacterial Therapeutics AB
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND,...
Ytterligare Infant Bacterial Therapeutics produkt beviljas “orphan drug” status av FDA
03 juil. 2023 10h39 HE
|
Infant Bacterial Therapeutics AB
FDA har beviljat särläkemedelsstatus för IBT:s produkt IBP-1016 för gastroschisis. Barn som drabbas av gastroschisis har ökade risker av tillväxthämning, sepsis och NEC vilket i sin tur...
Additional Infant Bacterial Therapeutics product receives FDA orphan drug designation
03 juil. 2023 10h39 HE
|
Infant Bacterial Therapeutics AB
The FDA has granted orphan drug designation for IBT’s product IBP-1016 for gastroschisis. Infants suffering from gastroschisis suffer from risks of growth retardation, sepsis and NEC which leads to...
The futility analysis for IBT’s Connection Study positive
21 juin 2023 11h20 HE
|
Infant Bacterial Therapeutics AB
“IBT announced earlier today that the Data Monitoring Committee (DMC) has performed the planned safety analysis of the study data of 1,403 babies. We have now also received results from the...